Grafted Polyglutamic Acid Stabilizes Interferon-Beta
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Interferon-beta (IFN-beta) pharmaceutical compositions face instability issues due to denaturation, aggregate formation, and chemical degradations, leading to reduced pharmaceutical utility and potential side effects, with existing solutions not providing satisfactory stability and sustained release profiles.
Innovation Solution
A sustained-release composition of IFN-beta is achieved by combining IFN-beta with specific grafted poly(glutamic acid) polymers, which enhances stability and solubility, allowing for once-a-week administration with reduced aggregate formation and improved bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IFN-beta is formulated in conventional pharmaceutical compositions, then it provides therapeutic activity, but it suffers from instability including denaturation, aggregate formation, and chemical degradation
Solution Approach 1:
The patent employs hydrophilic polymers (such as polyvinyl alcohol, polyethylene glycol, or carboxymethyl cellulose) as intermediary substances that interact with IFN-beta to prevent denaturation and aggregation. These polymer intermediaries form protective complexes with the interferon, stabilizing its three-dimensional structure and preventing harmful interactions with the aqueous environment, thereby resolving the stability contradiction.
Solution Approach 2:
The invention creates composite pharmaceutical compositions by combining IFN-beta with stabilizing polymers and excipients in specific ratios. This composite approach integrates multiple functional components: the active interferon molecule, stabilizing hydrophilic polymers, and auxiliary excipients, forming a synergistic system that maintains IFN-beta stability while enabling sustained release, thus simultaneously improving reliability and compositional stability.
2Reliability
If IFN-beta is administered frequently to maintain therapeutic levels, then therapeutic efficacy is improved, but patient convenience and compliance deteriorate
Solution Approach 1:
The patent utilizes the dynamic properties of hydrophilic polymers that exhibit temperature-sensitive solubility and viscosity changes. These polymers form gel-like structures at body temperature that slowly release IFN-beta, creating a dynamic release system that maintains therapeutic levels over extended periods. This dynamic behavior allows transition from frequent dosing to less frequent administration while maintaining efficacy, improving patient convenience.
Solution Approach 2:
The invention creates periodic release profiles where IFN-beta is released in controlled bursts or at steady rates over extended periods (days to weeks). This periodic action replaces the need for daily or frequent administrations with less frequent dosing intervals, maintaining therapeutic efficacy while significantly improving patient convenience and compliance.
3Reliability
If stabilizing excipients are added to IFN-beta compositions, then stability is improved, but the complexity of the formulation increases
Solution Approach 1:
The patent selects hydrophilic polymers that perform multiple functions simultaneously: they stabilize IFN-beta against denaturation and aggregation, provide sustained release through gel formation, and act as solubility enhancers. This multi-functionality reduces the need for multiple separate excipients, thereby improving stability while minimizing the increase in formulation complexity.
Solution Approach 2:
The invention optimizes specific parameters of the polymer excipients, such as molecular weight, degree of hydrolysis, and concentration ranges, to achieve maximum stabilizing effect with minimal formulation complexity. By carefully controlling these parameters within specific ranges, the formulation achieves high stability without requiring complex combinations of multiple excipients.
4Stability of the object's composition
If IFN-beta is stored at low temperatures to maintain stability, then degradation is reduced, but storage and distribution costs increase
Solution Approach 1:
The patent incorporates stabilizing hydrophilic polymers that provide beforehand cushioning protection to IFN-beta, creating a protective environment that prevents degradation pathways. This prior cushioning through polymer-IFN-beta interactions allows the interferon to remain stable at higher temperatures without requiring costly cold chain storage, thereby reducing storage energy costs while maintaining compositional stability.
Data Source
Figure 1
AI summary
The present invention pertains to interferon-beta (IFN-beta) compositions comprising interferon-beta and a grafted poly(glutamic acid) polymer having an average molecular weight between 26 000 and 40 000 g/mol, grafted with alpha-tocopherol substituants, the average molar grafting ratio being 4.5 - 5.5 moles %, the weight/weight ratio between said grafted poly(glutamic acid) polymer and IFN-beta being between 24 and 125. The present invention also pertains to the preparation methods of such compositions and their application to obtain therapeutic compositions in dosage unit form delivering IFN-beta over an extended period of time.